


Supplementary Figure 1 Translocator protein is upregulated in the colon tissues of patients with active inflammatory bowel diseases and influences the function of neutrophil. A: The numbers of translocator protein⁺ cells in each high-power field view are shown in the bar chart (${}^{b}P$ < 0.01); B: Histograms of fluorescence intensity of neutrophil extracellular traps detected by fluorometric plate reader (${}^{a}P$ < 0.05). n: the biologically independent replicates used in the statistical analyses. A-CD: Active Crohn's disease; A-UC: Active ulcerative colitis; TSPO: Translocator protein; HC: Healthy controls; PMA: Phorbol 12-myristate 13-acetate.



Supplementary Figure 2 Translocator protein is upregulated in the brains of mice with colitis.

A: Comparison of the initial weight of the two groups of mice; B: Statistical analysis and comparison of the brain standardized uptake value in the wild-type mice with H₂O and those with dextran sodium sulfate treatment (^{a}P < 0.05). n: The biologically independent replicates used in the statistical analyses DSS: Dextran sodium sulfate; SUV: Standardized uptake value; WT: Wild-type.

Supplementary Table 1 Clinical characteristics of inflammatory bowel diseases patients and healthy donors, n (%)

| Variable | Healthy | Active CD | CD in | Active UC | UC in |
|---------------------------|-------------|-------------|-------------|-------------|------------------|
| | controls | | remission | | remission |
| Number of patients | 35 | 47 | 18 | 40 | 25 |
| Age (years) | 37.0 (31.0- | 47.0 (32.0- | 45.5 (29.0- | 41.0 (31.0- | 51.0 (27-60.5) |
| | 49.0) | 58.0) | 55.3) | 54.5) | |
| Sex: Female | 15 (42.86) | 22 (46.81) | 7 (38.89) | 17 (42.50) | 14 (56.0) |
| Disease duration | | 20.0 (9.0- | 34.5 (18.5- | 29.5 (12.3- | 44.0 (19.5–53.0) |
| (months) | | 38.0) | 43.0) | 41.0) | |
| Disease locations for CD¹ | | | | | |
| L1 (ileal) | | 14 | 8 | | |
| L2 (colonic) | | 10 | 4 | | |
| L3 (ilecolonic) | | 21 | 6 | | |
| L4 (upper | | 2 | 0 | | |
| gastrointestinal tract) | | | | | |
| Disease locations for UC¹ | | | | | |
| E1 (proctitis) | | | | 18 | 12 |
| E2 (left-sided colitis) | | | | 16 | 9 |
| E3 (pancolitis) | | | | 6 | 4 |
| Current therapy | | | | | |
| 5-aminosalicyliclates | | 6 | 2 | 36 | 22 |
| Immunosuppressants | | 8 | 4 | 25 | 7 |
| Biologics | | 35 | 15 | 0 | 0 |
| Nutritional therapy | | 3 | 0 | 0 | 0 |

¹According to the Montreal classification.

CD: Crohn's disease; UC: Ulcerative colitis.